The Controversial Relationship Between Benign Prostat
The Role of Inflammation

European Urology

60, 106-117

DOI: 10.1016/j.eururo.2011.03.055

Citation Report

#	Article	IF	Citations
1	The role of inflammation in the pathogenesis of lung cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 1127-1137.	1.5	113
2	Anti-inflammatory and antiproliferative activities of date palm pollen (Phoenix dactylifera) on experimentally-induced atypical prostatic hyperplasia in rats. Journal of Inflammation, 2011, 8, 40.	1.5	47
4	Nonneoplastic Lesions of the Prostate and Bladder. Archives of Pathology and Laboratory Medicine, 2012, 136, 721-734.	1.2	27
5	Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis, 2012, 33, 2507-2519.	1.3	149
6	Fraction of Macroporous Resin from Smilax china L. Inhibits Testosterone Propionateâ€“Induced Prostatic Hyperplasia in Castrated Rats. Journal of Medicinal Food, 2012, 15, 646-650.	0.8	7
7	Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO Study. British Journal of Cancer, 2012, 107, 207-214.	2.9	52
8	Indications For and Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial. American Journal of Epidemiology, 2012, 176, 156-163.	1.6	23
9	Ciprofloxacin as a prophylactic agent against prostate cancer: A â€œtwo hitâ€•hypothesis. Medical Hypotheses, 2012, 78, 235-238.	0.8	6
10	Breaking through a roadblock in prostate cancer research: An update on human model systems. Journal of Steroid Biochemistry and Molecular Biology, 2012, 131, 122-131.	1.2	37
11	Patented prostate cancer biomarkers. Nature Reviews Urology, 2012, 9, 464-472.	1.9	15
12	Prostate Disease Risk Factors among a New Zealand Cohort. Journal of Nutrigenetics and Nutrigenomics, 2012, 5, 339-351.	1.8	36
13	Inhibition of Granzyme B by Plâ€9 protects prostate cancer cells from apoptosis. Prostate, 2012, 72, 846-855.	1.2	31
14	Reply to the impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer, 2012, 118, 5720-5720.	2.0	0
15	Serum Levels of Secreted Group IIA Phospholipase A2 in Benign Prostatic Hyperplasia and Prostate Cancer: A Biomarker for Inflammation or Neoplasia?. Inflammation, 2012, 35, 1113-1118.	1.7	21
16	The Correlation Between Metabolic Syndrome and Prostatic Diseases. European Urology, 2012, 61, 560-570.	0.9	297
17	Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCPâ€1/CCL2 and VCAMâ€1, in vitro. BJU International, 2012, 110, E301-7.	1.3	47
18	Effect of Serenoa repens (PermixonÂ®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma. Journal of Inflammation, 2013, 10, 11.	1.5	22
19	The Role of Inflammation in the Progression of Benign Prostatic Hyperplasia. Current Bladder Dysfunction Reports, 2013, 8, 142-149.	0.2	13

#	Article	IF	Citations
20	Diabetes and prostate cancerâ€"an open debate. Nature Reviews Urology, 2013, 10, 12-14.	1.9	11
21	Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: A prospective multicenter Italian cohort study. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 997-1002.	0.8	50
22	The Link Between Benign Prostatic Hyperplasia and Inflammation. European Urology Supplements, 2013, 12, 103-109.	0.1	19
23	Why and How to Evaluate Chronic Prostatic Inflammation. European Urology Supplements, 2013, 12, 110-115.	0.1	18
24	Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy. Clinical Genitourinary Cancer, 2013, 11, 423-430.	0.9	36
25	The link between benign prostatic hyperplasia and prostate cancer. Nature Reviews Urology, 2013, 10, 49-54.	1.9	129
26	Common genetic variants associated with disease from genomeâ€wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. BJU International, 2013, 111, 1148-1155.	1.3	9
27	3D-QSAR CoMFA and CoMSIA studies for design of potent human steroid 5Î±-reductase inhibitors. Medicinal Chemistry Research, 2013, 22, 105-114.	1.1	12
29	The Relationship Between Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and the Number of Components of Metabolic Syndrome. Urology, 2013, 82, 674-679.	0.5	59
30	Periurethral Fibrosis Secondary to Prostatic Inflammation Causing Lower Urinary Tract Symptoms: A Prospective Cohort Study. Urology, 2013, 81, 1018-1024.	0.5	66
31	Inflammation and prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 712.	0.8	2
32	LILRA3 Is Associated with Benign Prostatic Hyperplasia Risk in a Chinese Population. International Journal of Molecular Sciences, 2013, 14, 8832-8840.	1.8	7
33	The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (<scp>BPH</scp>). BJU International, 2013, 112, 432-441.	1.3	211
34	An introduction to acinar pressures in BPH and prostate cancer. Nature Reviews Urology, 2013, 10, 358-366.	1.9	7
35	Expression and role of the angiotensin II AT2 receptor in human prostate tissue: In search of a new therapeutic option for prostate cancer. Prostate, 2013, 73, 1057-1068.	1.2	22
36	CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer. Human Immunology, 2013, 74, 1003-1008.	1.2	25
37	Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk. British Journal of Cancer, 2013, 108, 1778-1783.	2.9	43
38	Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms. International Journal of Clinical Practice, 2013, 67, 1327-1333.	0.8	11

#	Article	IF	Citations
39	Serum amyloid A, phospholipase A2-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases. Inflammation Research, 2013, 62, 1063-1072.	1.6	17
40	Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. European Journal of Cancer, 2013, 49, 938-945.	1.3	65
41	Genetic factors regulating inflammation and DNA methylation associated with prostate cancer. Prostate Cancer and Prostatic Diseases, 2013, 16, 56-61.	2.0	40
42	Expression of protonâ€coupled oligopeptide transporter (POTs) in prostate of mice and patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Prostate, 2013, 73, 287-295.	1.2	10
43	Chronic asymptomatic inflammation of the prostate type IV and carcinoma of the prostate: Is there a correlation?. Scandinavian Journal of Urology, 2013, 47, 230-235.	0.6	17
44	The Impact of Obesity on Benign and Malignant Urologic Conditions. Postgraduate Medicine, 2013, 125, 53-69.	0.9	39
45	Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome. European Journal of Endocrinology, 2013, 169, 743-749.	1.9	18
46	Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocrine-Related Cancer, 2013, 20, R269-R290.	1.6	57
47	The Prognostic Use of Inflammation and Tissue Necrosis in Benign Prostatic Hyperplasia. Urologia Internationalis, 2013, 91, 19-25.	0.6	6
48	Correlation between benign prostatic hyperplasia and inflammation. Current Opinion in Urology, 2013, 23, 5-10.	0.9	122
49	Tollâ€like receptors in prostate infection and cancer between bench and bedside. Journal of Cellular and Molecular Medicine, 2013, 17, 713-722.	1.6	27
50	Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer and Prostatic Diseases, 2013, 16, 101-106.	2.0	132
52	Effects of Serenoa Repens, Selenium and Lycopene (ProflussÂ®) on chronic inflammation associated with Benign Prostatic Hyperplasia: results of â€œFLOGâ€•(Flogosis and Profluss in Prostatic and Genital) Tj ETQq0 0 0 rgBT /Overlock 10 Society of Urology, 2013, 39, 214-221.	0.7	46
53	Chronic inflammation of the prostate type IV with respect to risk of prostate cancer. Archivio Italiano Di Urologia Andrologia, 2014, 86, 208.	0.4	15
54	Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 356-366.	0.7	6
55	The Role of Inflammation in Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) and Its Potential Impact on Medical Therapy. Current Urology Reports, 2014, 15, 463.	1.0	92
56	Quality of Life and Sexual Health in the Aging of PCa Survivors. International Journal of Endocrinology, 2014, 2014, 1-16.	0.6	13
57	Immunomodulatory Effect of Red Onion (Allium cepaLinn) Scale Extract on Experimentally Induced Atypical Prostatic Hyperplasia in Wistar Rats. Mediators of Inflammation, 2014, 2014, 1-13.	1.4	39

#	Article	IF	Citations
58	Potential of grape seed-derived polyphenols extract for protection against testosterone-induced benign prostatic hyperplasia in castrated rats. RSC Advances, 2014, 4, 62996-63004.	1.7	6
59	Polarization of Prostate Cancer-associated Macrophages Is Induced by Milk Fat Globule-EGF Factor 8 (MFG-E8)-mediated Efferocytosis. Journal of Biological Chemistry, 2014, 289, 24560-24572.	1.6	140
60	Metabolic syndrome correlates with periâ€urethral fibrosis secondary to chronic prostate inflammation: Evidence of a link in a cohort of patients undergoing radical prostatectomy. International Journal of Urology, 2014, 21, 264-269.	0.5	18
61	Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. British Journal of Cancer, 2014, 111, 1421-1431.	2.9	26
62	Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate, 2014, 74, 1452-1461.	1.2	95
63	Senescent Remodeling of the Innate and Adaptive Immune System in the Elderly Men with Prostate Cancer. Current Gerontology and Geriatrics Research, 2014, 2014, 1-11.	1.6	18
64	Patients with metabolic syndrome and widespread high grade prostatic intraepithelial neoplasia are at a higher risk factor of prostate cancer on re-biopsy: A prospective single cohort study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 28.e27-28.e31.	0.8	6
65	Lycopene induce apoptosis in human prostate cells and alters the expression of Bax and Bcl-2 genes. LWT - Food Science and Technology, 2014, 59, 1290-1297.	2.5	24
66	An early-detection programme for prostate cancer in Saudi men: A call from a tertiary-care centre in the Eastern province. Arab Journal of Urology Arab Association of Urology, 2014, 12, 187-191.	0.7	11
67	Aspirin Use is Associated with Lower Prostate Cancer Risk in Male Carriers of BRCA Mutations. Journal of Genetic Counseling, 2014, 23, 187-191.	0.9	11
68	Prostate cell lines as models for biomarker discovery: Performance of current markers and the search for new biomarkers. Prostate, 2014, 74, 547-560.	1.2	18
69	The strategies to control prostate cancer by chemoprevention approaches. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 760, 1-15.	0.4	30
70	Metabolic Syndrome and Lower Urinary Tract Symptoms in Patients With Benign Prostatic Enlargement: A Possible Link to Storage Symptoms. Urology, 2014, 84, 1181-1187.	0.5	50
71	The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. Urology, 2014, 84, 1073-1080.	0.5	2
72	Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. European Urology, 2014, 66, 619-622.	0.9	57
73	Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate. Laboratory Investigation, 2014, 94, 208-221.	1.7	46
74	The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. Clinical Biochemistry, 2014, 47, 909-915.	0.8	31
75	Robotic-assisted laparoscopic prostatectomy in men with metabolic syndrome. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 40.e9-40.e16.	0.8	10

#	Article	IF	Citations
76	Protective effects of grape seed-derived procyanidin extract against carrageenan-induced abacterial prostatitis in rats. Journal of Functional Foods, 2014, 7, 416-424.	1.6	16
77	Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study. Asian Journal of Urology, 2015, 2, 224-232.	0.5	6
78	Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive rat. Prostate, 2015, 75, 1774-1782.	1.2	5
79	Incidence of benign prostate hypertrophy in Danish men with and without HIV infection. Aids, 2015, 29, 2315-2322.	1.0	2
80	Prostatic diseases under focus in a university hospital in Eastern Saudi Arabia. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 1319-1323.	0.5	0
81	Expression of Heat Shock Protein 27 in Benign Prostatic Hyperplasia with Chronic Inflammation. Medical Science Monitor, 2015, 21, 2976-2985.	0.5	9
82	Clinical Significance of National Institutes of Health-Chronic Prostatitis Symptom Index Pain Score in Patients with Benign Prostatic Hyperplasia. Urogenital Tract Infection, 2015, 10, 102.	0.1	0
83	Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat. PLoS ONE, 2015, 10, e0133798.	1.1	15
84	How to Choose the Right Serenoa repens Extract. European Urology Supplements, 2015, 14, e1464-e1469.	0.1	9
85	Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer. British Journal of Cancer, 2015, 112, 755-764.	2.9	62
86	Inflammation and prostate cancer: friends or foe?. Inflammation Research, 2015, 64, 275-286.	1.6	48
87	Tumor necrosis factor-Î± expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scandinavian Journal of Urology, 2015, 49, 472-478.	0.6	8
88	Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9722-9727.	3.3	53
89	Patients With Prostatic Inflammation Undergoing Transurethral Prostatic Resection Have a Larger Early Improvement of Storage Symptoms. Urology, 2015, 86, 359-367.	0.5	17
90	Antiâ€inflammatory properties of Lipidosterolic extract of Serenoa repens (PermixonÂ®) in a mouse model of prostate hyperplasia. Prostate, 2015, 75, 706-722.	1.2	36
91	Prostate Volume Index and Chronic Inflammation of the Prostate Type IV with Respect to the Risk of Prostate Cancer. Urologia Internationalis, 2015, 94, 270-285.	0.6	36
92	Prostate Biopsy Markers of Inflammation are Associated with Risk of Clinical Progression of Benign Prostatic Hyperplasia: Findings from the MTOPS Study. Journal of Urology, 2015, 194, 454-461.	0.2	68
93	In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles. International Journal of Molecular Sciences, 2015, 16, 9573-9587.	1.8	49

#	Article	IF	Citations
94	Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: Association with asymptomatic inflammatory prostatitis NIH category IV. Scandinavian Journal of Urology, 2015, 49, 120-126.	0.6	19
95	Smoking and Prostate Cancer: A Systematic Review. European Urology Focus, 2015, 1, 28-38.	1.6	41
96	Prevalence of Prostatic Calcification Subtypes and Association With Prostate Cancer. Urology, 2015, 85, 178-181.	0.5	24
97	Influence ofE. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. Prostate, 2015, 75, 381-389.	1.2	26
98	Coexisting Prostate Cancer Found at the Time of Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia: Predicting Its Presence and Grade in Analyzed Tissue. Journal of Endourology, 2015, 29, 41-46.	1.1	38
99	The relationship between histological prostatitis and lower urinary tract symptoms and sexual function. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 540-545.	0.7	8
100	Metabolic syndrome and prostatic disease: potentially role of polyphenols in preventive strategies. A review. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 422-430.	0.7	10
101	Prostate Cancer: Is It a Battle Lost to Age?. Geriatrics (Switzerland), 2016, 1, 27.	0.6	11
102	Fruit and Vegetable Intake in Relation to Lower Urinary Tract Symptoms and Erectile Dysfunction Among Southern Chinese Elderly Men. Medicine (United States), 2016, 95, e2557.	0.4	23
103	Disorder, Promiscuous Interactions, and Stochasticity Regulate State Switching in the Unstable Prostate. Journal of Cellular Biochemistry, 2016, 117, 2235-2240.	1.2	5
104	Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review. Journal of Inflammation, 2016, 13, 35.	1.5	52
105	Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy. BMC Cancer, 2016, 16, 329.	1.1	26
106	The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells. Immunity, 2016, 44, 1177-1189.	6.6	162
107	Statin Medications and Development and Progression of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. Current Bladder Dysfunction Reports, 2016, 11, 146-152.	0.2	0
108	Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nature Reviews Urology, 2016, 13, 613-626.	1.9	155
109	Benign Prostatic Hyperplasia, Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: Is Metaflammation the Link?. Prostate, 2016, 76, 1528-1535.	1.2	29
110	Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis. BJU International, 2016, 117, E29-35.	1.3	33
111	Dietary Phytochemicals and Cancer Chemoprevention: A Perspective on Oxidative Stress, Inflammation, and Epigenetics. Chemical Research in Toxicology, 2016, 29, 2071-2095.	1.7	77

#	Article	IF	Citations
112	New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives. BMC Urology, 2016, 16, 58.	0.6	19
113	Editorial Comment to Molecular classification of benign prostatic hyperplasia: A gene expression profiling study in a rat model. International Journal of Urology, 2016, 23, 612-613.	0.5	0
114	Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First Biopsy. Current Urology, 2016, 9, 82-92.	0.4	9
115	An association between diet, metabolic syndrome and lower urinary tract symptoms. African Journal of Urology, 2016, 22, 61-66.	0.1	8
116	Coordinated induction of cell survival signaling in the inflamed microenvironment of the prostate. Prostate, 2016, 76, 722-734.	1.2	8
117	Regulation of prostate cancer progression by the tumor microenvironment. Cancer Letters, 2016, 380, 340-348.	3.2	166
118	Are strict vegetarians protected against prostate cancer?. American Journal of Clinical Nutrition, 2016, 103, 153-160.	2.2	75
119	Macrophages, Inflammation, and Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 116-130.	2.5	206
120	Sensitivity improvement of a sandwich-type ELISA immunosensor for the detection of different prostate-specific antigen isoforms in human serum using electrochemical impedance spectroscopy and an ordered and hierarchically organized interfacial supramolecular architecture. Analytica Chimica Acta, 2016, 902, 97-106.	2.6	16
121	Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer and Prostatic Diseases, 2016, 19, 7-13.	2.0	61
122	Coffee inhibits nuclear factor-kappa B in prostate cancer cells and xenografts. Journal of Nutritional Biochemistry, 2016, 27, 153-163.	1.9	15
123	Pharmacological Role of Dietary Polyphenols in Prostate Cancer Chemoprevention. , 2016, , 239-251.		1
124	Physiological Roles of Bradykinin and Involvement of Bradykinin <scp>B2</scp> Receptor in Urethral Function in Humans and Animals. LUTS: Lower Urinary Tract Symptoms, 2017, 9, 187-191.	0.6	0
125	The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis. Experimental and Therapeutic Medicine, 2017, 13, 1025-1031.	0.8	5
126	Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis. Antioxidants and Redox Signaling, 2017, 26, 1078-1090.	2.5	23
127	The anti-hyperplasia, anti-oxidative and anti-inflammatory properties of Qing Ye Dan and swertiamarin in testosterone-induced benign prostatic hyperplasia in rats. Toxicology Letters, 2017, 265, 9-16.	0.4	45
128	The role of prostatic inflammation in the development and progression of benign and malignant diseases. Current Opinion in Urology, 2017, 27, 99-106.	0.9	54
129	Metabolic syndrome and benign prostatic hyperplasia: An update. Asian Journal of Urology, 2017, 4, 164-173.	0.5	34

#	Article	IF	Citations
130	Prostate Volume Index Associates with a Decreased Risk of Prostate Cancer: Results of a Large Cohort of Patients Elected to a First Biopsy Set. Urologia Internationalis, 2017, 98, 22-27.	0.6	10
131	Epigallocatechin-3-gallate reduces the proliferation of benign prostatic hyperplasia cells via regulation of focal adhesions. Life Sciences, 2017, 191, 74-81.	2.0	17
132	Comparison of serum acetyl hydrolase (PAF-AH) and paraoxonase 1 (PON1) values between prostate cancer patients and a control group. Kaohsiung Journal of Medical Sciences, 2017, 33, 572-577.	0.8	5
133	Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Differentiation, 2017, 96, 49-61.	1.0	48
134	Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the Î±-adrenergic receptor antagonist. Aging Male, 2017, 20, 250-256.	0.9	10
135	Changes in Weight and Metabolic Syndrome Are Associated With Prostate Growth Rate Over a 5-Year Period. Urology, 2017, 103, 185-190.	0.5	8
136	Intraprostatic Chronic Inflammation is Associated with a Reduced Risk of Prostate Cancer in Patients Elected to a First Random Biopsy Set. Tumori, 2017, 103, 475-482.	0.6	10
137	Prostate Volume Index Stratified Prostate Cancer Risk in Patients Elected to a First Random Biopsy Set. Tumori, 2017, 103, 374-379.	0.6	6
138	Inflammation in Prostatic Hyperplasia and Carcinomaâ€"Basic Scientific Approach. Frontiers in Oncology, 2017, 7, 77.	1.3	48
139	Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth. BMC Cancer, 2017, 17, 878.	1.1	52
140	Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia. International Urology and Nephrology, 2018, 50, 611-617.	0.6	10
141	Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 240.e1-240.e11.	0.8	20
142	Inverse Association of Prostatic Chronic Inflammation among Prostate Cancer Tumor Grade Groups: Retrospective Study of 738 Consecutive Cases Elected to a First Random Biopsy Set. Urologia Internationalis, 2018, 100, 456-462.	0.6	14
143	Vitamin D deficiency promotes prostatic hyperplasia in middle-age mice through exacerbating local inflammation. Journal of Steroid Biochemistry and Molecular Biology, 2018, 182, 14-20.	1.2	9
144	Associations of Transitional Zone Volume with Intraprostatic Chronic Inflammation and Prostate Cancer Risk in Patients Undergoing a First Random Biopsy Set. Current Urology, 2018, 11, 85-91.	0.4	5
145	Mechanism underlying the negative effect of prostate volume on the outcome of extensive transperineal ultrasoundâ€guided template prostate biopsy. Cancer Medicine, 2018, 7, 336-343.	1.3	4
146	An electrochemical approach capable of prostate specific antigen assay in human serum based on exonuclease-aided target recycling amplification. Sensors and Actuators B: Chemical, 2018, 257, 1021-1026.	4.0	26
147	Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction. Prostate Cancer and Prostatic Diseases, 2018, 21, 161-167.	2.0	15

#	Article	IF	Citations
148	The Correlation of Prostate Volume and Prostate-specific Antigen Levels With Positive Bacterial Prostate Tissue Cultures. Urology, 2018, 115, 151-156.	0.5	3
149	Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients. Prostate, 2018, 78, 17-24.	1.2	18
150	Immune profiling of human prostate epithelial cells determined by expression of p38/TRAFâ€6/ERK MAP kinases pathways. Kaohsiung Journal of Medical Sciences, 2018, 34, 125-133.	0.8	5
151	Myeloperoxidase and Prostate volume: A preliminary study. Progres En Urologie, 2018, 28, 482-487.	0.3	1
152	Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms. Investigative and Clinical Urology, 2018, 59, 399.	1.0	20
153	Intraurethral injection with LPS: an effective experimental model of prostatic inflammation. Inflammation Research, 2018, 67, 43-55.	1.6	22
154	Searching for the Novel Specific Predictors of Prostate Cancer in Urine: The Analysis of 84 miRNA Expression. International Journal of Molecular Sciences, 2018, 19, 4088.	1.8	32
155	Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. Journal of Clinical Medicine, 2018, 7, 156.	1.0	10
156	Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy. Frontiers in Oncology, 2018, 8, 438.	1.3	29
157	Macrophage Cytokines Enhance Cell Proliferation of Normal Prostate Epithelial Cells through Activation of ERK and Akt. Scientific Reports, 2018, 8, 7718.	1.6	53
158	Identification and preliminary study of immunogens involved in autoimmune prostatitis in human males. Prostate, 2018, 78, 1092-1102.	1.2	11
159	The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer. Frontiers in Immunology, 2018, 9, 1188.	2.2	46
160	Graminex Pollen: Phenolic Pattern, Colorimetric Analysis and Protective Effects in Immortalized Prostate Cells (PC3) and Rat Prostate Challenged with LPS. Molecules, 2018, 23, 1145.	1.7	55
161	Increased inflammatory potential of diet is associated with increased odds of prostate cancer in Argentinian men. Cancer Causes and Control, 2018, 29, 803-813.	0.8	17
162	Association between dietary flavonoids intake and prostate cancer risk: A case-control study in Sicily. Complementary Therapies in Medicine, 2018, 39, 14-18.	1.3	25
163	The cardiovascular risk factors in men with lower urinary tract symptoms. World Journal of Urology, 2019, 37, 727-733.	1.2	8
164	The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study. World Journal of Urology, 2019, 37, 539-544.	1.2	28
165	Prostate volume index and prostatic chronic inflammation have an effect on tumor load at baseline random biopsies in patients with normal DRE and PSA values less than 10â€‰ng/ml: results of 564 consecutive cases. Therapeutic Advances in Urology, 2019, 11, 175628721986860.	0.9	5

#	Article	IF	Citations
166	Current Knowledge of the Potential Links between Inflammation and Prostate Cancer. International Journal of Molecular Sciences, 2019, 20, 3833.	1.8	65
167	Cucurbitacin E glucoside from Citrullus colocynthis inhibits testosterone-induced benign prostatic hyperplasia in mice. Drug and Chemical Toxicology, 2021, 44, 533-543.	1.2	9
168	Search for Novel Diagnostic Biomarkers of Prostate Inflammation-Related Disorders: Role of Transglutaminase Isoforms as Potential Candidates. Mediators of Inflammation, 2019, 2019, 1-10.	1.4	5
169	Quantitation of Lipid Peroxidation Product DNA Adducts in Human Prostate by Tandem Mass Spectrometry: A Method That Mitigates Artifacts. Chemical Research in Toxicology, 2019, 32, 1850-1862.	1.7	9
170	Does chronic obstructive pulmonary disease increase the risk of prostate cancer? A nationwide population-based study . International Journal of COPD, 2019, Volume 14, 1913-1921.	0.9	4
171	Prostate Volume Index Is Able to Differentiate between Prostatic Chronic Inflammation and Prostate Cancer in Patients with Normal Digital Rectal Examination and Prostate-Specific Antigen Values <10 ng/mL: Results of 564 Biopsy NaÃ¯ve Cases. Urologia Internationalis, 2019, 103, 415-422.	0.6	7
172	The Expression of Transforming Growth Factor Beta-1 and Interleukin-6 on Human Prostate: Prostate Hyperplasia and Prostate Cancer. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 1905-1910.	0.1	7
173	Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. Prostate Cancer and Prostatic Diseases, 2019, 22, 475-482.	2.0	28
174	Urinary Biomarkers and Benign Prostatic Hyperplasia. Current Bladder Dysfunction Reports, 2019, 14, 31-40.	0.2	3
175	Hyperglycemia and T Cell infiltration are associated with stromal and epithelial prostatic hyperplasia in the nonobese diabetic mouse. Prostate, 2019, 79, 980-993.	1.2	12
176	Combined Sabal and Urtica Extracts (WSÂ® 1541) Exert Anti-proliferative and Anti-inflammatory Effects in a Mouse Model of Benign Prostate Hyperplasia. Frontiers in Pharmacology, 2019, 10, 311.	1.6	18
177	Upregulated Interleukin 21 Receptor Enhances Proliferation and Epithelial-Mesenchymal Transition Process in Benign Prostatic Hyperplasia. Frontiers in Endocrinology, 2019, 10, 4.	1.5	14
178	Association of antiâ€inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice. Prostate, 2019, 79, 515-535.	1.2	8
179	Tumorâ€“Microenvironment Interaction: Analysis of Mast Cell Populations in Normal Tissue and Proliferative Disorders of the Canine Prostate. Veterinary Sciences, 2019, 6, 16.	0.6	4
180	A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 2047-2054.	1.1	11
181	Prostate resected weight and postoperative prostate cancer incidence after transurethral resection of the prostate. Medicine (United States), 2019, 98, e13897.	0.4	9
182	Complement activation by autoantigen recognition in the growth process of benign prostatic hyperplasia. Scientific Reports, 2019, 9, 20357.	1.6	10
183	Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L.. Journal of Ethnopharmacology, 2019, 232, 1-10.	2.0	36

#	Article	IF	Citations
184	Phosphodiesterase type 5 inhibitor attenuates chronic ischemiaâ€induced prostatic hyperplasia in a rat model. Prostate, 2019, 79, 536-543.	1.2	11
185	A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer. Translational Research, 2019, 206, 91-106.	2.2	20
186	Physical Activity as a Protective Factor for Lower Urinary Tract Symptoms in Male Patients: A Prospective Cohort Analysis. Urology, 2019, 125, 163-168.	0.5	13
187	Tadalafil: 15 years' journey in male erectile dysfunction and beyond. Drug Development Research, 2019, 80, 683-701.	1.4	16
188	An immunohistochemical study of T and B lymphocyte density in prostatic hyperplasia and prostate carcinoma in dogs. Research in Veterinary Science, 2019, 122, 189-192.	0.9	6
189	Association between Dietary Inflammatory Index and the Risk of Prostate Cancer: A Meta-Analysis. Nutrition and Cancer, 2019, 71, 359-366.	0.9	28
190	Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU). European Urology Focus, 2019, 5, 756-787.	1.6	52
191	Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy. World Journal of Urology, 2020, 38, 957-964.	1.2	11
192	Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines. Fundamental and Clinical Pharmacology, 2020, 34, 160-172.	1.0	35
193	Inflammatory serum markers and risk and severity of prostate cancer: The PROCAâ€life study. International Journal of Cancer, 2020, 147, 84-92.	2.3	26
194	Nonneoplastic Diseases of the Prostate. , 2020, , 358-414.e13.		0
195	Association between the neutrophilâ€toâ€lymphocyte ratio and intravesical prostatic protrusion in men with benign prostatic hyperplasia. LUTS: Lower Urinary Tract Symptoms, 2020, 12, 62-67.	0.6	4
196	The effect of spironolactone on thyroid autoimmunity in euthyroid men with Hashimoto's thyroiditis. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 152-159.	0.7	3
197	PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer. FASEB Journal, 2020, 34, 1304-1318.	0.2	15
198	Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A systematic review and Meta-analysis. Journal of Cancer, 2020, 11, 177-189.	1.2	33
199	External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers. World Journal of Urology, 2020, 38, 2555-2561.	1.2	5
200	Phenotypic switching and prostate diseases: a model proposing a causal link between benign prostatic hyperplasia and prostate cancer. , 2020, , 569-589.		0
201	Prediction of clinically significant prostate cancer after negative prostate biopsy: The current value of microscopic findings. Urologic Oncology: Seminars and Original Investigations, 2020, 39, 432.e11-432.e19.	0.8	0

#	Article	IF	Citations
202	Obesity and Prostate Cancer: The Tip of a High Mountain Still to Be Conquered. Journal of Clinical Medicine, 2020, 9, 2070.	1.0	3
203	The Crosstalk between Prostate Cancer and Microbiota Inflammation: Nutraceutical Products Are Useful to Balance This Interplay?. Nutrients, 2020, 12, 2648.	1.7	42
204	Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study. PLoS ONE, 2020, 15, e0238928.	1.1	0
205	Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naÃ¯ve prostate cancer. Prostate, 2020, 80, 1353-1364.	1.2	4
206	Lower thiol, glutathione, and glutathione peroxidase levels in prostate cancer: a meta-analysis study. Aging Male, 2020, 23, 1533-1544.	0.9	8
207	Piceatannol Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by Modulation of Nrf2/HO-1/NFÎºB Axis. Frontiers in Pharmacology, 2020, 11, 614897.	1.6	17
208	Prostatic chronic inflammation and prostate cancer risk at baseline random biopsy: Analysis of predictors. Arab Journal of Urology Arab Association of Urology, 2020, 18, 148-154.	0.7	3
209	Estrogen regulates the proliferation and inflammatory expression of primary stromal cell in benign prostatic hyperplasia. Translational Andrology and Urology, 2020, 9, 322-331.	0.6	9
210	Irvingia excelsa Mildbr. ethanolic extract displays in vitro cytotoxic effects on prostate cancer cells and prevents benign prostatic hyperplasia in Wistar rats. Biologia (Poland), 2020, 75, 2053-2062.	0.8	3
211	Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 793.e19-793.e25.	0.8	13
212	Gene Expression-Based Immune Cell Infiltration Analyses of Prostate Cancer and Their Associations with Survival Outcome. DNA and Cell Biology, 2020, 39, 1194-1204.	0.9	8
213	The protective effect of Sophora japonica on prostatic hypertrophy and inflammation in rat. Inflammopharmacology, 2020, 28, 1525-1536.	1.9	9
214	Thiol Groups as a Biomarker for the Diagnosis and Prognosis of Prostate Cancer. Scientific Reports, 2020, 10, 9093.	1.6	9
215	Is there a correlation between the aggressiveness of chronic asymptomatic prostatitis NIH category IV and the Gleason score in patients with prostate cancer?. Canadian Urological Association Journal, 2020, 14, E568-E573.	0.3	4
216	Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats. European Journal of Pharmacology, 2020, 882, 173313.	1.7	7
217	Ethanolâ€extracted Cameroonian propolis: Antiproliferative effects and potential mechanism of action in prostate cancer. Andrologia, 2020, 52, e13698.	1.0	6
218	Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2020, 13, 853-862.	0.7	8
219	Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World Journal of Urology, 2020, 38, 2771-2779.	1.2	36

#	Article	IF	Citations
220	Detection of Prostatic Inflammation From Peripheral Lymphocyte Count and Free/Total PSA Ratio in Men With LUTS/BPH. Frontiers in Pharmacology, 2020, 11, 589.	1.6	5
221	The Clinical Impact of Hexanic Extract of Serenoa repens in Men with Prostatic Inflammation: A Post Hoc Analysis of a Randomized Biopsy Study. Journal of Clinical Medicine, 2020, 9, 957.	1.0	2
222	Human microbiome and prostate cancer development: current insights into the prevention and treatment. Frontiers of Medicine, 2021, 15, 11-32.	1.5	17
223	Prostatic stromal proliferations: a review. Pathology, 2021, 53, 12-25.	0.3	6
224	Prostate-Specific Deletion of Cdh1 Induces Murine Prostatic Inflammation and Bladder Overactivity. Endocrinology, 2021, 162, .	1.4	9
225	Benign prostatic hyperplasia â€“ what do we know?. BJU International, 2021, 127, 389-399.	1.3	90
226	Association of the inflammatory potential of diet and lower urinary tract symptoms among men in the United States. Aging Male, 2021, 24, 72-79.	0.9	2
227	The Effect Of Epigallocatechin-3-Gallate On Transcriptional Regulation Of Migration And Inflammation Related Genes In Benign Prostate Hyperplasia Cells. Celal Bayar Ãœniversitesi SaÄŸlÄ±k Bilimleri EnstitÃ¼sÃ¼ Dergisi, 0, , .	0.1	1
228	Therapeutic effects of losartan on prostatic hyperplasia in spontaneously hypertensive rats. Life Sciences, 2021, 266, 118924.	2.0	4
229	Circular RNA circ_0057558 Controls Prostate Cancer Cell Proliferation Through Regulating miR-206/USP33/c-Myc Axis. Frontiers in Cell and Developmental Biology, 2021, 9, 644397.	1.8	22
230	In Silico and In Vitro Study: COX-2 Inhibition by Ethanol Extract of Dayak Onion Bulb (Eleutherine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Anti-Allergy Agents in Medicinal Chemistry, 2021, 20, 68-74.	1.1	2
231	M2a macrophage can rescue proliferation and gene expression of benign prostate hyperplasia epithelial and stroma cells from insulinâ€like growth factor 1 knockdown. Prostate, 2021, 81, 530-542.	1.2	9
232	Therapeutic Applications of Functional Nanomaterials for Prostatitis. Frontiers in Pharmacology, 2021, 12, 685465.	1.6	8
233	Valor actual de los hallazgos histolÃ³gicos de biopsias de prÃ³stata negativas en la predicciÃ³n del riesgo futuro de cÃ¡ncer de prÃ³stata clÃnicamente significativo. Actas UrolÃ³gicas EspaÃ±olas, 2021, 45, 447-454.	0.3	2
235	Therapeutic effects of Î²â€caryophyllene on proliferative disorders and inflammation of the gerbil prostate. Prostate, 2021, 81, 812-824.	1.2	2
236	Inhibitory Activities of Dimeric Ellagitannins Isolated from Cornus alba on Benign Prostatic Hypertrophy. Molecules, 2021, 26, 3446.	1.7	3
237	Potential role of glutathione S-transferase P1 gene polymorphism and metabolic syndrome in lower urinary tract symptoms attributed to benign prostatic hyperplasia. World Journal of Urology, 2021, 39, 4413-4419.	1.2	0
238	GSTP1 as a novel target in radiation induced lung injury. Journal of Translational Medicine, 2021, 19, 297.	1.8	12

#	Article	IF	Citations
239	Cellular senescence as a possible link between prostate diseases of the ageing male. Nature Reviews Urology, 2021, 18, 597-610.	1.9	19
240	The current value of histological findings in negative prostate biopsies to predict the future risk of clinically significant prostate cancer. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2021, 45, 447-454.	0.2	0
241	The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers. Frontiers in Immunology, 2021, 12, 721989.	2.2	13
242	Changes in diagnosis rate and treatment trends of benign prostatic hyperplasia in Korea: A nationwide population-based cohort study. Prostate International, 2021, 9, 215-220.	1.2	12
243	Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis. Biochemia Medica, 2015, 25, 439-449.	1.2	10
244	Expression of Tripartite Motif-Containing Proteactiin 11 (TRIM11) is Associated with the Progression of Human Prostate Cancer and is Downregulated by MicroRNA-5193. Medical Science Monitor, 2019, 25, 98-106.	0.5	23
245	Prevalence of and Risk Factors for Asymptomatic Inï¬‚ammatory (NIH-IV) Prostatitis in Chinese Men. PLoS ONE, 2013, 8, e71298.	1.1	15
246	Correlations of Metabolic Components with Prostate Volume in Middle-Aged Men Receiving Health Check-Up. PLoS ONE, 2016, 11, e0145050.	1.1	4
247	Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients. PLoS ONE, 2016, 11, e0147739.	1.1	13
248	The mysterious relation between inflammation and prostate cancer. Infection International, 2017, 6, 8-12.	0.1	2
249	Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis. Aging, 2020, 12, 2142-2155.	1.4	21
250	Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Oncotarget, 2017, 8, 50904-50910.	0.8	13
251	Peripheral zone volume ratio (PZ-ratio) is relevant with biopsy results and can increase the accuracy of current diagnostic modality. Oncotarget, 2017, 8, 34836-34843.	0.8	10
252	Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget, 2017, 8, 46710-46727.	0.8	25
253	Endosomal gene expression: a new indicator for prostate cancer patient prognosis?. Oncotarget, 2015, 6, 37919-37929.	0.8	36
254	IL-27/IL-27RA signaling may modulate inflammation and progression of benign prostatic hyperplasia via suppressing the LPS/TLR4 pathway. Translational Cancer Research, 2020, 9, 4618-4634.	0.4	2
255	Elevated Tumor Necrosis Factor-Î± and Transforming Growth Factor-Î² in Prostatic Tissue are Risk Factors for Lower Urinary Tract Symptoms after Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia Patients with Urinary Retention. The Open Urology & Nephrology Journal, 2018, 11, 46-53.	0.2	3
256	Association of Some Polymorphisms in the VDR Gene, CYP17 Gene and SRD5A2 Gene and Prostate Cancer among Lebanese Men. Asian Pacific Journal of Cancer Prevention, 2017, 18, 93-100.	0.5	9

#	Article	IF	Citations
257	BPH and prostate cancer risk. Indian Journal of Urology, 2014, 30, 214.	0.2	48
258	The effect of metabolic syndrome on prostate cancer final pathology. Journal of Cancer Research and Therapeutics, 2019, 15, 47.	0.3	4
259	Peripheral monocyte count: an independent diagnostic and prognostic biomarker for prostate cancer - a large Chinese cohort study. Asian Journal of Andrology, 2017, 19, 579.	0.8	21
260	Toll-like receptor 10 (TLR10) exhibits suppressive effects on inflammation of prostate epithelial cells. Asian Journal of Andrology, 2019, 21, 393.	0.8	13
261	Is the Neutrophil-Lymphocyte Ratio an Indicator of Progression in Patients with Benign Prostatic Hyperplasia?. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6375-6379.	0.5	21
262	Hiperplasia ProstÃ¡tica Benigna e PSA: o efeito dominÃ³. Revista Brasileira De Medicina De FamÃlia E Comunidade, 2012, 7, 259-264.	0.1	0
263	Epidemiology and Pathophysiology of LUTS/BPO. , 2014, , 21-31.		0
265	Effects of Peanut Sprout (Arachis hypogaea L.) Extract on Partial Androgen Deficiency in Aging Males (PADAM). Journal of the Korean Society of Food Science and Nutrition, 2016, 45, 1571-1579.	0.2	1
266	Chapter 11 Zyfl amend and Prostate Cancer Therapy. Traditional Herbal Medicines for Modern Times, 2016, , 197-220.	0.1	0
267	Does asymptomatic prostatic inflammation alter the outcome of transurethral resection of prostate?. Central European Journal of Urology, 2017, 70, 252-258.	0.2	2
268	The impact of lymphocytic infiltrates on the progression of benign prostatic hyperplasia to prostatic carcinoma. Egyptian Journal of Pathology, 2017, 37, 360-366.	0.0	0
269	Aspirin in the Management of Patients with Prostate Cancer Undergoing Radiotherapy: Friend or Foe?. Anticancer Research, 2018, 38, 1897-1902.	0.5	4
270	The Early Prediction of Prostate Cancer and Benign Prostate Hyperplasia Additional to Rutin Examination. Bozok TÄ±p Dergisi, 0, , .	0.0	0
273	La prolstata desde una perspectiva inmunolol̀gica. Medicina Y Laboratorio, 2020, 24, 13-35.	0.0	0
274	Light-controlled calcium signalling in prostate cancer and benign prostatic hyperplasia. Future Journal of Pharmaceutical Sciences, 2020, 6, .	1.1	1
275	Cyclopamine functions as a suppressor of benign prostatic hyperplasia by inhibiting epithelial and stromal cell proliferation via suppression of the Hedgehog signaling pathway. International Journal of Molecular Medicine, 2020, 46, 311-319.	1.8	7
276	Bacterial Lipopolysaccharide Augmented Malignant Transformation and Promoted the Stemness in Prostate Cancer Epithelial Cells. Journal of Inflammation Research, 2021, Volume 14, 5849-5862.	1.6	6
277	Benign Prostatik Patolojilerde RegÃ¼latuvar T HÃ¼crelerinin (Treg) DeÄŸerlendirilmesi: Pilot Ã‡alÄ±ÅŸma. KahramanmaraÅŸ SÃ¼tÃ§Ã¼ Ä°mam Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.1	0

#	Article	IF	Citations
278	Elevated red blood cell distribution width in benign prostatic hyperplasia patients with metabolic syndrome. International Journal of Clinical and Experimental Medicine, 2015, 8, 1213-9.	1.3	4
279	A novel method to identify and isolate proliferative inflammatory atrophy (PIA) clusters and to extract high-quality PIA RNA. International Journal of Clinical and Experimental Pathology, 2015, 8, 3987-93.	0.5	0
280	Association between oral pathogens and prostate cancer: building the relationship. American Journal of Clinical and Experimental Urology, 2019, 7, 1-10.	0.4	7
281	Expression of ARHGAP10 correlates with prognosis of prostate cancer. International Journal of Clinical and Experimental Pathology, 2019, 12, 3839-3846.	0.5	4
282	Associations of gene polymorphisms with the development and clinical progression of benign prostatic hyperplasia: a case-control study in northern Chinese population. International Journal of Clinical and Experimental Pathology, 2017, 10, 8660-8676.	0.5	1
283	Pathological characteristics of CD40/CD40L and NF-Î²B proteins related to inflammation in benign prostatic hyperplasia tissue: a retrospective study of 120 cases. International Journal of Clinical and Experimental Pathology, 2017, 10, 10863-10872.	0.5	1
284	Role of sex hormone on morphological and histological changes in benign prostatic hypertrophy rats. International Journal of Clinical and Experimental Pathology, 2017, 10, 10821-10829.	0.5	0
285	Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. American Journal of Translational Research (discontinued), 2021, 13, 3868-3889.	0.0	4
286	Identifying prognostic signatures in the microenvironment of prostate cancer. Translational Andrology and Urology, 2021, 10, 4206-4218.	0.6	3
287	Impairment of autophagy may represent the molecular mechanism behind the relationship between obesity and inflammation in patients with BPH and LUTS. Minerva Urology and Nephrology, 2021, 73, 631-637.	1.3	7
288	Metabolic syndrome and male lower urinary tract symptoms. Panminerva Medica, 2022, 64, .	0.2	2
289	Prognostic significance of SDF-1 chemokine and its receptors CXCR4 and CXCR7 involved in EMT of prostate cancer. Cytokine, 2022, 150, 155778.	1.4	8
290	The prostate cancer landscape in Europe: Current challenges, future opportunities. Cancer Letters, 2022, 526, 304-310.	3.2	16
291	The onset of age-related benign prostatic hyperplasia is concomitant with increased serum and prostatic expression of VEGF in rats: Potential role of VEGF as a marker for early prostatic alterations. Theriogenology, 2022, 183, 69-78.	0.9	1
293	Metabolic Syndrome and Physical Inactivity May Be Shared Etiological Agents of Prostate Cancer and Coronary Heart Diseases. Cancers, 2022, 14, 936.	1.7	5
294	Immune Cell Proinflammatory Microenvironment and Androgen-Related Metabolic Regulation During Benign Prostatic Hyperplasia in Aging. Frontiers in Immunology, 2022, 13, 842008.	2.2	7
295	Phosphodiesterase 5 inhibitor suppresses prostate weight increase in type 2 diabetic rats. Life Sciences, 2022, 298, 120504.	2.0	2
296	Effects of Exercise on Serum Inflammatory Markers and NF-kb, COX-2 mRNA Expression in Prostate of BPH-Induced Mice. Exercise Science, 2021, 30, 510-516.	0.1	0

#	Article	IF	Citations
297	Phosphodiesterase 5 Inhibitor Suppresses Prostate Weight Increase in Type 2 Diabetic Rats. SSRN Electronic Journal, 0, , .	0.4	0
307	Applications of Vertebrate Models in Studying Prostatitis and Inflammation-Associated Prostatic Diseases. Frontiers in Molecular Biosciences, 0, 9, .	1.6	2
308	Evaluation of the Therapeutic Effect of the Traditional Herbal Medicine Atrifil and Oshagh Gum on Testosterone-Induced Benign Prostatic Hyperplasia in Wistar Rats. Advances in Urology, 2022, 2022, 1-14.	0.6	4
309	Association of Cytokine Gene Polymorphisms with Prostate Cancer Risk from a Study in Central China. Contrast Media and Molecular Imaging, 2022, 2022, 1-11.	0.4	3
310	Is periodontal disease a risk indicator for urogenital cancer? A systematic review and meta-analysis of cohort studies. Frontiers in Oncology, 0, 12, .	1.3	0
311	Prostate diseases: pathogenetic bases and therapeutic possibilities of entomotherapy. Andrologia I Genital'naa Hirurgia, 2022, 23, 29-40.	0.1	0
313	Research Progress on the Relationship between C-Reactive Protein and Prostate Cancer during Endocrine Drug Therapy. Advances in Clinical Medicine, 2022, 12, 9551-9556.	0.0	0
314	Association between interleukin-6 and lower urinary tract symptoms of benign prostatic hyperplasia. Revista Internacional De AndrologÃa, 2023, 21, 100334.	0.1	0
315	Postâ€prostaticâ€massage urine exosomes of men with chronic prostatitis/chronic pelvic pain syndrome carry prostateâ€cancerâ€typical micro‹scp›RNA‹/scp›s and activate protoâ€oncogenes. Molecular Oncology, 2023, 17, 445-468.	2.1	0
316	Application of Modern Analytical Techniques for quantification of Tadalafil in Pharmaceutical and Biological Matrices: Future Prospectus.. Current Pharmaceutical Analysis, 2022, 19, .	0.3	0
317	The Role of Combination Therapy with Î±-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH. Journal of Clinical Medicine, 2022, 11, 7169.	1.0	4
318	Changes in the Expression and Functional Activities of C-X-C Motif Chemokine Ligand 13 (CXCL13) in Hyperplastic Prostate. International Journal of Molecular Sciences, 2023, 24, 56.	1.8	5
319	Clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation: A prospective research study. Frontiers in Surgery, 0, 9, .	0.6	0
320	Traditional Chinese Medicine Danzhi qing'e decoction inhibits inflammation-associated prostatic hyperplasia via inactivation of ERK1/2 signal pathway. Journal of Ethnopharmacology, 2023, 309, 116354.	2.0	0
321	Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges. Seminars in Cancer Biology, 2023, 91, 70-98.	4.3	8
322	The Emerging Role of Cell Adhesion Molecules on Benign Prostatic Hyperplasia. International Journal of Molecular Sciences, 2023, 24, 2870.	1.8	1
323	Toxicoproteomics of Mono(2-ethylhexyl) phthalate and Perfluorooctanesulfonic Acid in Models of Prostatic Diseases. Chemical Research in Toxicology, 2023, 36, 251-259.	1.7	3
324	InflamaciÃ³n y cÃ¡ncer de prÃ³stata: implicaciones biolÃ³gicas y posible utilidad clÃ¬nica. Iatreia, 2013, 27, .	0.1	0

#	Article	IF	Citations
325	Prostatic Inflammation is Determinant for Prostate Overgrowth and Luts Severity in Men with Metabolic Syndrome: Highlights from Two Recently Published Multicentre Studies. European Medical Journal Urology, 0, , 78-82.	0.0	0
326	Research of Prostate Cancer Urinary Diagnostic Biomarkers by Proteomics: The Noteworthy Influence of Inflammation. Diagnostics, 2023, 13, 1318.	1.3	0
327	Targeting benign prostate hyperplasia treatments: AR/TGF-Î²/NOX4 inhibition by apocynin suppresses inflammation and proliferation. Journal of Advanced Research, 2024, 57, 135-147.	4.4	4
328	Genetically predicted alterations in thyroid function are associated with the risk of benign prostatic disease. Frontiers in Endocrinology, 0, 14, .	1.5	2